First Header Logo Second Header Logo

Connection

Nancy King to Human Experimentation

This is a "connection" page, showing publications Nancy King has written about Human Experimentation.
Connection Strength

3.090
  1. King NMP. Key Information in the New Common Rule: Can It Save Research Consent? J Law Med Ethics. 2019 06; 47(2):203-212.
    View in: PubMed
    Score: 0.695
  2. King NM. Who's Winning the IRB Wars? The Struggle for the Soul of Human Research. Perspect Biol Med. 2018; 61(3):450-464.
    View in: PubMed
    Score: 0.630
  3. King NM. Nanomedicine first-in-human research: challenges for informed consent. J Law Med Ethics. 2012; 40(4):823-30.
    View in: PubMed
    Score: 0.416
  4. King NM, Iltis AS. Introduction: research ethics: reexamining key concerns. J Law Med Ethics. 2012; 40(4):865-6.
    View in: PubMed
    Score: 0.416
  5. Henderson GE, Davis AM, King NM. Vulnerability to influence: a two-way street. Am J Bioeth. 2004; 4(3):50-2; discussion W32.
    View in: PubMed
    Score: 0.239
  6. King NM. The line between clinical innovation and human experimentation. Seton Hall Law Rev. 2003; 32(3):571-80.
    View in: PubMed
    Score: 0.223
  7. Churchill LR, King NM, Henderson GE. Why we should continue to worry about the therapeutic misconception. J Clin Ethics. 2013; 24(4):381-6.
    View in: PubMed
    Score: 0.111
  8. Fatehi L, Wolf SM, McCullough J, Hall R, Lawrenz F, Kahn JP, Jones C, Campbell SA, Dresser RS, Erdman AG, Haynes CL, Hoerr RA, Hogle LF, Keane MA, Khushf G, King NM, Kokkoli E, Marchant G, Maynard AD, Philbert M, Ramachandran G, Siegel RA, Wickline S. Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging field. J Law Med Ethics. 2012; 40(4):716-50.
    View in: PubMed
    Score: 0.104
  9. Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, Kass N, King NM, Lidz CW, Miller FG, Nelson DK, Peppercorn J, Rothschild BB, Sankar P, Wilfond BS, Zimmer CR. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med. 2007 Nov 27; 4(11):e324.
    View in: PubMed
    Score: 0.078
  10. Churchill LR, Nelson DK, Henderson GE, King NM, Davis AM, Leahey E, Wilfond BS. Assessing benefits in clinical research: why diversity in benefit assessment can be risky. IRB. 2003 May-Jun; 25(3):1-8.
    View in: PubMed
    Score: 0.057
  11. King NM. RAC oversight of gene transfer research: a model worth extending? J Law Med Ethics. 2002; 30(3):381-9.
    View in: PubMed
    Score: 0.052
  12. King NM. Health policy--ensuring informed consent in human experimentation: a comparison of the approaches of two states. North Carol Law Rev. 1979 Oct; 58(1):137-52.
    View in: PubMed
    Score: 0.044
  13. King NM, Henderson G. Treatments of last resort: informed consent and the diffusion of new technology. Mercer Law Rev. 1991; 42(3):1007-50.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.